{
    "reg_info": {
        "full_title": "O. Reg. 112/11: DESIGNATED DRUGS AND STANDARDS OF PRACTICE",
        "reg_name_text": "Designated Drugs and Standards of Practice",
        "citation": "O. Reg. 112/11: DESIGNATED DRUGS AND STANDARDS OF PRACTICE",
        "act_under": "Optometry Act, 1991   Loi de 1991 sur les optométristes",
        "url": "https://www.ontario.ca/laws/regulation/110112",
        "date_scraped": "2023-12-19 02:58:56"
    },
    "copyright": {
        "Copyright": "© King's Printer for Ontario, 2023."
    },
    "versions": [
        {
            "a_href": "/laws/about-e-laws#ccl",
            "valid_from": "February  6, 2017",
            "valid_to": "current"
        },
        {
            "a_href": "/laws/regulation/110112/v1",
            "valid_from": "April  5, 2011",
            "valid_to": "February  5, 2017"
        }
    ],
    "content": [
        {
            "id": "1.",
            "section": "Drugs that may be prescribed",
            "content": "  1. For the purposes of paragraph 2.1 of section 4 of the Act, and subject to sections 2, 3 and 4 and Part II of this Regulation, a member may prescribe a drug set out under a category and sub-category heading in Schedule 1.  O. Reg. 112/11, s. 1.",
            "raw_html": "<p class=\"section-e\"><b>  1.</b> For the purposes of paragraph 2.1 of section 4 of the Act, and subject to sections 2, 3 and 4 and Part II of this Regulation, a member may prescribe a drug set out under a category and sub-category heading in Schedule 1.  O. Reg. 112/11, s. 1.</p>"
        },
        {
            "id": "2.",
            "section": "Limitations",
            "content": " 2. Where a limitation or a route of administration is indicated with respect to a drug listed in Schedule 1, either in a sub-category heading or with respect to that particular drug, a member shall only prescribe the drug in compliance with the limitation and in accordance with the route of administration specified. O. Reg. 17/17, s. 1.",
            "raw_html": "<p class=\"section-e\"> <b>2. </b>Where a limitation or a route of administration is indicated with respect to a drug listed in Schedule 1, either in a sub-category heading or with respect to that particular drug, a member shall only prescribe the drug in compliance with the limitation and in accordance with the route of administration specified. O. Reg. 17/17, s. 1.</p>"
        },
        {
            "id": "3.",
            "section": "Training required",
            "content": "  3. No member may prescribe any drug unless he or she has successfully completed the relevant training in pharmacology that has been approved by the Council.  O. Reg. 112/11, s. 3.",
            "raw_html": "<p class=\"section-e\"><b>  3. </b>No member may prescribe any drug unless he or she has successfully completed the relevant training in pharmacology that has been approved by the Council.  O. Reg. 112/11, s. 3.</p>"
        },
        {
            "id": "4.",
            "section": "Recording ",
            "content": "  4. Every time a member prescribes a drug the member shall record the following in the patient’s health record as that record is required to be kept under section 10 of Ontario Regulation 119/94 (General) made under the Act: 1. Details of the prescription, including the drug prescribed, dosage and route of administration. 2. Details of the counselling provided by the member to or on behalf of the patient respecting the use of the drug prescribed.  O. Reg. 112/11, s. 4.",
            "raw_html": "<p class=\"section-e\"><b>  4.</b> Every time a member prescribes a drug the member shall record the following in the patient’s health record as that record is required to be kept under section 10 of Ontario Regulation 119/94 (General) made under the Act:</p> <p class=\"paragraph-e\">  1. Details of the prescription, including the drug prescribed, dosage and route of administration.</p> <p class=\"paragraph-e\"><i> </i>2. Details of the counselling provided by the member to or on behalf of the patient respecting the use of the drug prescribed.  O. Reg. 112/11, s. 4.</p>"
        },
        {
            "id": "5.",
            "section": "Non-prescription drugs",
            "content": "  5. In the course of engaging in the practice of optometry a member may prescribe any drug that may lawfully be purchased or acquired without a prescription.  O. Reg. 112/11, s. 5. Part II   Standards of Practice — Glaucoma",
            "raw_html": "<p class=\"section-e\"><b><span>  5.</span></b><span> In the course of engaging in the practice of optometry a</span> member may prescribe any drug that may lawfully be purchased or acquired without a prescription.  O. Reg. 112/11, s. 5.</p> <p class=\"partnum-e\">Part II <br/>  Standards of Practice — Glaucoma</p>"
        },
        {
            "id": "6.",
            "section": "Prescribing of antiglaucoma agents",
            "content": " 6. It is a standard of practice of the profession that in treating glaucoma a member may only prescribe a drug set out under the category of “Antiglaucoma Agents” in Schedule 1.  O. Reg. 112/11, s. 6.",
            "raw_html": "<p class=\"section-e\"> <b>6. </b>It is a standard of practice of the profession that in treating glaucoma a member may only prescribe a drug set out under the category of “Antiglaucoma Agents” in Schedule 1.  O. Reg. 112/11, s. 6.</p>"
        },
        {
            "id": "7.",
            "section": "Open-angle glaucoma",
            "content": " 7. (1) Subject to subsection (2) and to section 8, it is a standard of practice of the profession that a member may only treat a patient with glaucoma where the patient has primary open-angle glaucoma the treatment of which is not complicated by either a concurrent medical condition or a potentially interacting pharmacological treatment.  O. Reg. 112/11, s. 7 (1). (2) It is a standard of practice of the profession that a member may only treat a patient having open-angle glaucoma, the treatment of which is complicated by either a concurrent medical condition or a potentially interacting pharmacological treatment, in collaboration with a physician with whom the member has established a co-management model of care for that patient and who is, (a) certified by the Royal College of Physicians and Surgeons of Canada as a specialist in ophthalmology; or (b) formally recognized in writing by the College of Physicians and Surgeons of Ontario as a specialist in ophthalmology.  O. Reg. 112/11, s. 7 (2).",
            "raw_html": "<p class=\"section-e\"> <b>7. </b>(1) Subject to subsection (2) and to section 8, it is a standard of practice of the profession that a member may only treat a patient with glaucoma where the patient has primary open-angle glaucoma the treatment of which is not complicated by either a concurrent medical condition or a potentially interacting pharmacological treatment.  O. Reg. 112/11, s. 7 (1).</p> <p class=\"subsection-e\">  (2) It is a standard of practice of the profession that a member may only treat a patient having open-angle glaucoma, the treatment of which is complicated by either a concurrent medical condition or a potentially interacting pharmacological treatment, in collaboration with a physician with whom the member has established a co-management model of care for that patient and who is,</p> <p class=\"clause-e\">  (a) certified by the Royal College of Physicians and Surgeons of Canada as a specialist in ophthalmology; or </p> <p class=\"clause-e\">  (b) formally recognized in writing by the College of Physicians and Surgeons of Ontario as a specialist in ophthalmology.  O. Reg. 112/11, s. 7 (2).</p>"
        },
        {
            "id": "8.",
            "section": "Referral to physician or hospital",
            "content": "  8. (1) Subject to subsections (2) and (3), it is a standard of practice of the profession that a member shall immediately refer a patient having a form of glaucoma other than primary open-angle glaucoma to a physician or to a hospital.  O. Reg. 112/11, s. 8 (1). (2) It is a standard of practice of the profession that a member may initiate treatment for a patient having angle-closure glaucoma only in an emergency and where no physician is available to treat the patient.  O. Reg. 112/11, s. 8 (2). (3) It is a standard of practice of the profession that a member shall immediately refer any patient being treated in accordance with subsection (2) to a physician or hospital once the emergency no longer exists or once a physician becomes available, whichever comes first.  O. Reg. 112/11, s. 8 (3). (4) In this section, “hospital” means a hospital within the meaning of the Public Hospitals Act.  O. Reg. 112/11, s. 8 (4).",
            "raw_html": "<p class=\"section-e\"><b>  8.</b> (1) Subject to subsections (2) and (3), it is a standard of practice of the profession that a member shall immediately refer a patient having a form of glaucoma other than primary open-angle glaucoma to a physician or to a hospital.  O. Reg. 112/11, s. 8 (1).</p> <p class=\"subsection-e\">  (2) It is a standard of practice of the profession that a member may initiate treatment for a patient having angle-closure glaucoma only in an emergency and where no physician is available to treat the patient.  O. Reg. 112/11, s. 8 (2).</p> <p class=\"subsection-e\">  (3) It is a standard of practice of the profession that a member shall immediately refer any patient being treated in accordance with subsection (2) to a physician or hospital once the emergency no longer exists or once a physician becomes available, whichever comes first.  O. Reg. 112/11, s. 8 (3).</p> <p class=\"subsection-e\">  (4) In this section,</p> <p class=\"firstdef-e\">“hospital” means a hospital within the meaning of the <i>Public Hospitals Act.</i>  O. Reg. 112/11, s. 8 (4).</p>"
        },
        {
            "id": "9.",
            "section": "Referral to physician or hospital",
            "content": " 9. Omitted (provides for coming into force of provisions of this Regulation).  O. Reg. 112/11, s. 9. SCHEDULE 1 ANTI-INFECTIVE AGENTS Antibacterials (topical) azithromycin besifloxacin ciprofloxacin erythromycin framycetin fusidic acid gatifloxacin gentamicin moxifloxacin ofloxacin polymyxin B/gramicidin/neomycin polymyxin B/neomycin/ bacitracin polymyxin B/trimethoprim sulfacetamide tetracycline tobramycin Antifungals (topical) natamycin Antivirals (topical) trifluridine Acyclovir Antibacterials (oral) – for corneal or eyelid infections only and for a duration not exceeding 14 days amoxicillin amoxicillin/clavulanic acid azithromycin cephalexin ciprofloxacin clarithromycin clindamycin cloxacillin doxycycline erythromycin levofloxacin minocycline moxifloxacin tetracycline Antivirals (oral) – for corneal or eyelid infections only acyclovir famciclovir valacyclovir ANTI-INFLAMMATORY AGENTS Corticosteroids (topical) dexamethasone difluprednate fluorometholone loteprednol prednisolone rimexolone Corticosteroids (topical) – for the purpose of treating conditions of the eye and adnexa triamcinolone Immunomodulators (topical) cyclosporine Nonsteroidal anti-inflammatory agents (topical) bromfenac diclofenac ketorolac nepafenac ANTI-INFECTIVE/ANTI-INFLAMMATORY AGENTS Antibacterials /corticosteroids (topical) framycetin/gramicidin/dexamethasone gentamicin/betamethasone neomycin/fluorometholone neomycin/polymyxin B/dexamethasone neomycin/bacitracin/polymyxin B/hydrocortisone sulfacetamide/prednisolone tobramycin/dexamethasone MYDRIATICS Mydriatics (topical) atropine cyclopentolate homatropine tropicamide ANTI-ALLERGIC AGENTS Antiallergic agents (topical) bepotastine emedastine ketotifen levocabastine lodoxamide nedocromil olopatadine tacrolimus – for the purpose of treating conditions of the eye and adnexa and for a duration not exceeding 42 days ANTIGLAUCOMA AGENTS β-Adrenergic blocking agents (topical) betaxolol levobunolol timolol Carbonic anhydrase inhibitors (topical) brinzolamide dorzolamide Miotics (topical) carbachol pilocarpine Prostaglandin analogs (topical) bimatoprost latanoprost tafluprost travoprost α-Adrenergic agonists (topical) apraclonidine brimonidine α-Adrenergic agonists/β-adrenergic blocking agents (topical) brimonidine/timolol Carbonic anhydrase inhibitors/β-adrenergic blocking agents (topical) brinzolamide/timolol dorzolamide/timolol Prostaglandin analogs/β-adrenergic blocking agents (topical) latanoprost/timolol travoprost/timolol Carbonic anhydrase inhibitors (oral) – to lower intraocular pressure only and a member shall immediately refer the patient to a physician or to a hospital acetazolamide SECRETAGOGUES Secretagogues (oral) – for Sjögren’s syndrome only and only in collaboration with a physician with whom the member has established a co-management model of care pilocarpine O. Reg. 112/11, Sched. 1; O. Reg. 17/17, s. 2.    ",
            "raw_html": "<p class=\"section-e\"> <b>9.</b> <span class=\"ovsmallcap\">Omitted</span> (<span class=\"ovsmallcap\">provides for coming into force of provisions of this Regulation</span>).  O. Reg. 112/11, s. 9.</p> <p class=\"schedule-e\">SCHEDULE 1</p> <p class=\"paranoindt-e\">ANTI-INFECTIVE AGENTS</p> <p class=\"parawindt-e\">Antibacterials (topical)</p> <p class=\"parawindt2-e\">  azithromycin </p> <p class=\"parawindt2-e\">  besifloxacin  </p> <p class=\"parawindt2-e\">  ciprofloxacin </p> <p class=\"parawindt2-e\">  erythromycin </p> <p class=\"parawindt2-e\">  framycetin  </p> <p class=\"parawindt2-e\">  fusidic acid  </p> <p class=\"parawindt2-e\">  gatifloxacin</p> <p class=\"parawindt2-e\">  gentamicin </p> <p class=\"parawindt2-e\">  moxifloxacin  </p> <p class=\"parawindt2-e\">  ofloxacin </p> <p class=\"parawindt2-e\">  polymyxin B/gramicidin/neomycin </p> <p class=\"parawindt2-e\">  polymyxin B/neomycin/ bacitracin</p> <p class=\"parawindt2-e\">  polymyxin B/trimethoprim  </p> <p class=\"parawindt2-e\">  sulfacetamide </p> <p class=\"parawindt2-e\">  tetracycline</p> <p class=\"parawindt2-e\">  tobramycin  </p> <p class=\"parawindt-e\">Antifungals (topical)</p> <p class=\"parawindt2-e\">  natamycin</p> <p class=\"parawindt-e\">Antivirals (topical)</p> <p class=\"parawindt2-e\">  trifluridine</p> <p class=\"parawindt2-e\">  Acyclovir</p> <p class=\"parawindt-e\">Antibacterials (oral) – for corneal or eyelid infections only and for a duration not exceeding 14 days</p> <p class=\"parawindt2-e\">  amoxicillin</p> <p class=\"parawindt2-e\">  amoxicillin/clavulanic acid</p> <p class=\"parawindt2-e\">  azithromycin  </p> <p class=\"parawindt2-e\">  cephalexin</p> <p class=\"parawindt2-e\">  ciprofloxacin  </p> <p class=\"parawindt2-e\">  clarithromycin</p> <p class=\"parawindt2-e\">  clindamycin</p> <p class=\"parawindt2-e\">  cloxacillin</p> <p class=\"parawindt2-e\">  doxycycline </p> <p class=\"parawindt2-e\">  erythromycin  </p> <p class=\"parawindt2-e\">  levofloxacin  </p> <p class=\"parawindt2-e\">  minocycline </p> <p class=\"parawindt2-e\">  moxifloxacin </p> <p class=\"parawindt2-e\">  tetracycline</p> <p class=\"parawindt-e\">Antivirals (oral) – for corneal or eyelid infections only</p> <p class=\"parawindt2-e\">  acyclovir  </p> <p class=\"parawindt2-e\">  famciclovir </p> <p class=\"parawindt2-e\">  valacyclovir  </p> <p class=\"paranoindt-e\">ANTI-INFLAMMATORY AGENTS</p> <p class=\"parawindt-e\">Corticosteroids (topical)</p> <p class=\"parawindt2-e\">  dexamethasone</p> <p class=\"parawindt2-e\">  difluprednate</p> <p class=\"parawindt2-e\">  fluorometholone </p> <p class=\"parawindt2-e\">  loteprednol</p> <p class=\"parawindt2-e\">  prednisolone </p> <p class=\"parawindt2-e\">  rimexolone</p> <p class=\"parawindt-e\">Corticosteroids (topical) – for the purpose of treating conditions of the eye and adnexa</p> <p class=\"parawindt2-e\">  triamcinolone</p> <p class=\"parawindt-e\">Immunomodulators (topical)</p> <p class=\"parawindt2-e\">  cyclosporine</p> <p class=\"parawindt-e\">Nonsteroidal anti-inflammatory agents (topical)</p> <p class=\"parawindt2-e\">  bromfenac</p> <p class=\"parawindt2-e\">  diclofenac </p> <p class=\"parawindt2-e\">  ketorolac </p> <p class=\"parawindt2-e\">  nepafenac</p> <p class=\"paranoindt-e\">ANTI-INFECTIVE/ANTI-INFLAMMATORY AGENTS</p> <p class=\"parawindt-e\">Antibacterials /corticosteroids (topical)</p> <p class=\"parawindt2-e\">  framycetin/gramicidin/dexamethasone</p> <p class=\"parawindt2-e\">  gentamicin/betamethasone </p> <p class=\"parawindt2-e\">  neomycin/fluorometholone </p> <p class=\"parawindt2-e\">  neomycin/polymyxin B/dexamethasone </p> <p class=\"parawindt2-e\">  neomycin/bacitracin/polymyxin B/hydrocortisone</p> <p class=\"parawindt2-e\">  sulfacetamide/prednisolone </p> <p class=\"parawindt2-e\">  tobramycin/dexamethasone</p> <p class=\"paranoindt-e\">MYDRIATICS</p> <p class=\"parawindt-e\">Mydriatics (topical)</p> <p class=\"parawindt2-e\">  atropine  </p> <p class=\"parawindt2-e\">  cyclopentolate </p> <p class=\"parawindt2-e\">  homatropine</p> <p class=\"parawindt2-e\">  tropicamide</p> <p class=\"paranoindt-e\">ANTI-ALLERGIC AGENTS</p> <p class=\"parawindt-e\">Antiallergic agents (topical)</p> <p class=\"parawindt2-e\">  bepotastine</p> <p class=\"parawindt2-e\">  emedastine</p> <p class=\"parawindt2-e\">  ketotifen </p> <p class=\"parawindt2-e\">  levocabastine</p> <p class=\"parawindt2-e\">  lodoxamide </p> <p class=\"parawindt2-e\">  nedocromil </p> <p class=\"parawindt2-e\">  olopatadine</p> <p class=\"parawindt2-e\">  tacrolimus – for the purpose of treating conditions of the eye and adnexa and for a duration not exceeding 42 days</p> <p class=\"paranoindt-e\">ANTIGLAUCOMA AGENTS</p> <p class=\"parawindt-e\">β-Adrenergic blocking agents (topical)</p> <p class=\"parawindt2-e\">  betaxolol </p> <p class=\"parawindt2-e\">  levobunolol</p> <p class=\"parawindt2-e\">  timolol</p> <p class=\"parawindt-e\">Carbonic anhydrase inhibitors (topical) </p> <p class=\"parawindt2-e\">  brinzolamide</p> <p class=\"parawindt2-e\">  dorzolamide</p> <p class=\"parawindt-e\">Miotics (topical)</p> <p class=\"parawindt2-e\">  carbachol </p> <p class=\"parawindt2-e\">  pilocarpine</p> <p class=\"parawindt-e\">Prostaglandin analogs (topical)</p> <p class=\"parawindt2-e\">  bimatoprost  </p> <p class=\"parawindt2-e\">  latanoprost  </p> <p class=\"parawindt2-e\">  tafluprost</p> <p class=\"parawindt2-e\">  travoprost</p> <p class=\"parawindt-e\">α-Adrenergic agonists (topical)</p> <p class=\"parawindt2-e\">  apraclonidine</p> <p class=\"parawindt2-e\">  brimonidine  </p> <p class=\"parawindt-e\">α-Adrenergic agonists/β-adrenergic blocking agents (topical)</p> <p class=\"parawindt2-e\">  brimonidine/timolol</p> <p class=\"parawindt-e\">Carbonic anhydrase inhibitors/β-adrenergic blocking agents (topical)</p> <p class=\"parawindt2-e\">  brinzolamide/timolol</p> <p class=\"parawindt2-e\">  dorzolamide/timolol</p> <p class=\"parawindt-e\">Prostaglandin analogs/β-adrenergic blocking agents (topical)</p> <p class=\"parawindt2-e\">  latanoprost/timolol</p> <p class=\"parawindt2-e\">  travoprost/timolol</p> <p class=\"parawindt-e\">Carbonic anhydrase inhibitors (oral) – to lower intraocular pressure only and a member shall immediately refer the patient to a physician or to a hospital</p> <p class=\"parawindt2-e\">  acetazolamide</p> <p class=\"paranoindt-e\">SECRETAGOGUES</p> <p class=\"parawindt-e\">Secretagogues (oral) – for Sjögren’s syndrome only and only in collaboration with a physician with whom the member has established a co-management model of care</p> <p class=\"parawindt2-e\">  pilocarpine</p> <p class=\"footnote-e\">O. Reg. 112/11, Sched. 1; O. Reg. 17/17, s. 2.</p> <p class=\"footnote-e\"> </p> <p class=\"MsoNormal\"> </p> <p class=\"MsoNormal\"> </p> <p class=\"MsoNormal\"></p>"
        }
    ]
}